Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | GAK | O14976 | 8/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202865 | 0.86 | PDGFRB (0.47) | PDGFRBPDGFRAFYNGAKCHEK1 | |
| SCHEMBL5203291 | 0.81 | CHEK1 (0.48) | PDGFRBPDGFRAFYNCHEK1CHEK2 | |
| SCHEMBL5936909 | 0.78 | PDGFRB (0.54) | PDGFRBPDGFRAFYNGAKCHEK1 | |
| SCHEMBL6028508 | 0.77 | FFAR1 (0.48) | PDGFRBPDGFRAFYNCHEK1CHEK2 | |
| SCHEMBL5202877 | 0.75 | PDGFRB (0.48) | PDGFRBPDGFRAFYNGAKCHEK1 | |
| SCHEMBL3769943 | 0.73 | PDGFRB (0.58) | PDGFRBPDGFRAFYNGAKCHEK1 | |
| SCHEMBL6029081 | 0.73 | PDGFRB (0.58) | PDGFRBPDGFRAFYNGAKCHEK1 | |
| SCHEMBL5202742 | 0.72 | RAB9A (0.48) | ALDH1A1KDM4EGAALMNAMAPT | |
| SCHEMBL8840880 | 0.71 | PDE4A (0.67) | PDGFRBPDGFRAALDH1A1KDM4EGAA | |
| SCHEMBL2399663 | 0.71 | CA2 (0.59) | ALDH1A1KDM4EGAAHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358181-B1 | SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| EP-1358181-A1 | SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20030199532-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | KERTESZ DENIS JOHN (US) | 2003-10-23 | — | — | US | disclosed |
| US-6552028-B2 | Inhibiting the binding of eotaxin to chemokine-3 (ccr-3) receptor; antiasthmatics | SYNTEX (U.S.A.) LLC | 2003-04-22 | — | — | US | disclosed |
| US-20020198255-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002050064-A1 | SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199532-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCR4 | PDGFRB 218/4885PDGFRA 222/4885FYN 2854/4885 |
| US-20020198255-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCR4 | PDGFRB 218/4885PDGFRA 222/4885FYN 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.